Combining popular diabetes drugs offers complementary heart and kidney benefits, research finds

New research shows combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against heart and kidney disease in patients with diabetes. The findings were published today in The Lancet Diabetes & Endocrinology and presented in May at the 61st European Renal Association Congress in Stockholm...

Get In Touch

479, Nuri Street 29

+6012 345 6495

mainportfolios@gmail.com

Follow Us
Flickr Photos

Copyright © 2024 fu.ci. All Rights Reserved